Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by N.J. Kenyon
Benralizumab: A Unique IL-5 Inhibitor for Severe Asthma
Journal of Asthma and Allergy
Immunology
Pulmonary
Allergy
Respiratory Medicine
Related publications
Benralizumab for the Treatment of Severe Eosinophilic Asthma
Prescriber
Pharmacology
Relationship Between Benralizumab Exposure and Efficacy for Patients With Severe Eosinophilic Asthma
Clinical Pharmacology and Therapeutics
Pharmacology
Benralizumab Efficacy for Patients With Fixed Airflow Obstruction and Severe, Uncontrolled Eosinophilic Asthma
Annals of Allergy, Asthma and Immunology
Respiratory Medicine
Pulmonary
Allergy
Immunology
The Clinical Profile of Benralizumab in the Management of Severe Eosinophilic Asthma
Therapeutic Advances in Respiratory Disease
Pulmonary
Respiratory Medicine
Pharmacology
Daily Patient-Reported Health Status Assessment Improvements With Benralizumab for Patients With Severe, Uncontrolled Eosinophilic Asthma
Journal of Asthma and Allergy
Immunology
Pulmonary
Allergy
Respiratory Medicine
Efficacy and Safety of Treatment With Biologicals (Benralizumab, Dupilumab, Mepolizumab, Omalizumab and Reslizumab) for Severe Eosinophilic Asthma
Allergy: European Journal of Allergy and Clinical Immunology
Allergy
Immunology
P68 Asthma Symptom Improvements With Benralizumab Are Associated With Improvements in Activity Functions and Quality of Life for Patients With Severe, Uncontrolled Asthma: Results of Pooled Phase Iii Benralizumab Studies
Benralizumab in the Treatment of Severe Asthma: Design, Development and Potential Place in Therapy
Drug Design, Development and Therapy
Drug Discovery
Pharmacology
Pharmaceutical Science
Anti-Interleukin-5 Therapy in Severe Asthma
European Respiratory Review
Pulmonary
Respiratory Medicine
